Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NASDAQ:CRNX NASDAQ:NBTX NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$46.16+0.3%$46.96$21.34▼$58.40$3.70B-0.291.20 million shs982,785 shsCRNXCrinetics Pharmaceuticals$42.23-0.6%$33.38$24.10▼$62.53$4.01B0.331.08 million shs3,240 shsNBTXNanobiotix$26.50+26.4%$10.88$2.76▼$25.12$1.26B0.723,202 shs24,899 shsZLABZai Lab$33.26+1.1%$33.74$23.82▼$44.34$3.72B1.08924,925 shs93,976 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics-0.09%-3.12%+2.86%-10.03%+71.96%CRNXCrinetics Pharmaceuticals+1.97%+2.04%+19.35%+31.46%-17.89%NBTXNanobiotix-7.95%+11.01%+145.41%+292.70%+310.37%ZLABZai Lab-1.26%-2.95%+6.92%-7.77%+24.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$46.16+0.3%$46.96$21.34▼$58.40$3.70B-0.291.20 million shs982,785 shsCRNXCrinetics Pharmaceuticals$42.23-0.6%$33.38$24.10▼$62.53$4.01B0.331.08 million shs3,240 shsNBTXNanobiotix$26.50+26.4%$10.88$2.76▼$25.12$1.26B0.723,202 shs24,899 shsZLABZai Lab$33.26+1.1%$33.74$23.82▼$44.34$3.72B1.08924,925 shs93,976 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics-0.09%-3.12%+2.86%-10.03%+71.96%CRNXCrinetics Pharmaceuticals+1.97%+2.04%+19.35%+31.46%-17.89%NBTXNanobiotix-7.95%+11.01%+145.41%+292.70%+310.37%ZLABZai Lab-1.26%-2.95%+6.92%-7.77%+24.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 2.78Moderate Buy$81.1475.79% UpsideCRNXCrinetics Pharmaceuticals 2.71Moderate Buy$74.4576.30% UpsideNBTXNanobiotix 2.25Hold$11.00-58.50% DownsideZLABZai Lab 2.63Moderate Buy$56.3569.45% UpsideCurrent Analyst Ratings BreakdownLatest NBTX, CRNX, ZLAB, and AKRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/30/2025CRNXCrinetics PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$73.00 ➝ $87.009/29/2025CRNXCrinetics PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$65.00 ➝ $77.009/29/2025CRNXCrinetics PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $88.009/27/2025AKROAkero TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CRNXCrinetics PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NBTXNanobiotixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ZLABZai LabWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/26/2025CRNXCrinetics PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$35.00 ➝ $40.009/26/2025CRNXCrinetics PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$86.00 ➝ $143.009/26/2025CRNXCrinetics PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$58.00 ➝ $62.009/24/2025CRNXCrinetics PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$53.00 ➝ $52.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/ACRNXCrinetics Pharmaceuticals$1.04M3,824.34N/AN/A$14.29 per share2.96NBTXNanobiotix$39.18M32.43N/AN/A($1.51) per share-17.55ZLABZai Lab$398.99M9.31N/AN/A$7.68 per share4.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$4.11N/AN/AN/AN/A-32.28%-29.45%11/6/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/AN/AZLABZai Lab-$257.10M-$2.04N/AN/AN/A-49.68%-27.32%-18.85%11/11/2025 (Estimated)Latest NBTX, CRNX, ZLAB, and AKRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13-$1.23-$0.10-$1.23$0.52 million$1.03 million8/7/2025Q2 2025ZLABZai Lab-$0.37-$0.37N/A-$0.37$125.66 million$109.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0212.6612.66CRNXCrinetics PharmaceuticalsN/A17.8017.80NBTXNanobiotixN/A0.63N/AZLABZai LabN/A3.122.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/ACRNXCrinetics Pharmaceuticals98.51%NBTXNanobiotix38.81%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%CRNXCrinetics Pharmaceuticals6.00%NBTXNanobiotix3.45%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableCRNXCrinetics Pharmaceuticals21094.18 million88.53 millionOptionableNBTXNanobiotix10047.94 million46.29 millionNot OptionableZLABZai Lab1,869111.76 million106.22 millionOptionableNBTX, CRNX, ZLAB, and AKRO HeadlinesRecent News About These CompaniesZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages5 hours ago | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?September 30, 2025 | marketbeat.comZai Lab (ZLAB) Gets a Buy from Cantor FitzgeraldSeptember 21, 2025 | theglobeandmail.com29,693 Shares in Zai Lab Limited Unsponsored ADR $ZLAB Purchased by Acadian Asset Management LLCSeptember 18, 2025 | marketbeat.comZai Lab Limited (ZLAB): A Bull Case TheorySeptember 16, 2025 | finance.yahoo.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from BrokeragesSeptember 15, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Insider Buys $289,100.00 in StockSeptember 14, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's What HappenedSeptember 13, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Insider Acquires $289,100.00 in StockSeptember 13, 2025 | insidertrades.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's WhySeptember 12, 2025 | marketbeat.comZai Lab's Double Whammy: Earnings Miss, Phase 3 SetbackSeptember 11, 2025 | benzinga.comWoodline Partners LP Lowers Stock Holdings in Zai Lab Limited Unsponsored ADR $ZLABSeptember 11, 2025 | marketbeat.comZai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comZai Lab FY2026 EPS Forecast Lowered by Leerink PartnrsSeptember 9, 2025 | marketbeat.comCubist Systematic Strategies LLC Has $3.38 Million Stock Position in Zai Lab Limited Unsponsored ADR $ZLABSeptember 8, 2025 | marketbeat.comRaymond James Financial Inc. Has $4.55 Million Holdings in Zai Lab Limited Unsponsored ADR $ZLABSeptember 8, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab ...September 6, 2025 | bakersfield.comBInstitutional investors may overlook Zai Lab Limited's (NASDAQ:ZLAB) recent US$260m market cap drop as long-term gains remain positiveSeptember 6, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLABSeptember 6, 2025 | globenewswire.comAmgen’s bemarituzumab loses momentum as survival edge fadesSeptember 5, 2025 | thepharmaletter.comTZai Lab to wait on results of FORTITUDE-102 prior to regulatory filingSeptember 3, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBTX, CRNX, ZLAB, and AKRO Company DescriptionsAkero Therapeutics NASDAQ:AKRO$46.16 +0.12 (+0.26%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Crinetics Pharmaceuticals NASDAQ:CRNX$42.23 -0.27 (-0.63%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Nanobiotix NASDAQ:NBTX$26.50 +5.53 (+26.39%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Zai Lab NASDAQ:ZLAB$33.26 +0.37 (+1.11%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
